NCT05131971

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants

A Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3888130B in Healthy Participants Aged 18-55 Inclusive

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a first time in human study designed to assess the safety, tolerability, pharmacokinetics and PD of GSK3888130B over a range of dose levels in healthy participants.

Conditions

• Multiple Sclerosis
• Colitis, Ulcerative

Interventions

Type	Name	Description
DRUG	GSK3888130B	GSK3888130B will be administered.
DRUG	Placebo	Placebo will be administered.

Timeline

• Start date: 2021-11-01
• Primary completion: 2023-10-12
• Completion: 2023-10-12
• First posted: 2021-11-23
• Last updated: 2025-03-26
• Results posted: 2025-03-26

Locations

1 site across 1 country: United Kingdom